Last reviewed · How we verify
Aspirin combined with half-dose ticagrelor
Aspirin combined with half-dose ticagrelor is a Small molecule drug developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. It is currently FDA-approved.
Aspirin combined with half-dose ticagrelor, marketed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, holds a unique position in the antiplatelet therapy market. The key composition patent expires in 2028, providing a strong barrier to generic competition and maintaining market exclusivity. However, the lack of detailed primary trial results and revenue data poses a significant risk in assessing the drug's long-term market performance and competitive landscape.
At a glance
| Generic name | Aspirin combined with half-dose ticagrelor |
|---|---|
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin combined with half-dose ticagrelor CI brief — competitive landscape report
- Aspirin combined with half-dose ticagrelor updates RSS · CI watch RSS
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School portfolio CI